Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 9/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL17222518 | 0.95 | SLC22A1 (0.48) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL4603559 | 0.95 | DNM1 (0.48) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL2772679 | 0.95 | DNM1 (0.48) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| Bromide SCHEMBL3028711 | 0.90 | SLC22A1 (0.41) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL8500577 | 0.87 | SLC22A1 (0.43) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| SCHEMBL17222516 | 0.87 | SLC22A1 (0.41) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL315435 | 0.86 | DNM1 (0.44) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| Hydrochloric Acid SCHEMBL8500446 | 0.85 | SLC22A1 (0.41) | TSHRHSD17B10DNM1SLC22A1RAD52 | |
| Hydrochloric Acid SCHEMBL2764924 | 0.85 | DNM1 (0.43) | ALDH1A1TP53CYP3A4ALOX15TSHR | |
| Phosphoric Acid SCHEMBL10748115 | 0.84 | GGPS1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6346516-B1 | DRUG DELIVERY OF (QUATERNARY) AMINE SALT AND MACROMOLECULE; GENE THERAPY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2002-02-12 | — | — | US | claimed |
| US-20230145420-A1 | RECOMBINANT VACCINES AND METHODS OF USE THEREOF | VANDERBILT UNIVERSITY | 2023-05-11 | — | — | US | disclosed |
| EP-4132572-A1 | RECOMBINANT VACCINES AND METHODS OF USE THEREOF | Vanderbilt University (US) | 2023-02-15 | — | — | EP | disclosed |
| EP-2891497-B1 | DNA VACCINE CONTAINING VEGF-SPECIFIC EPITOPE AND/OR ANGIOPOIETIN-2-SPECIFIC EPITOPE | UNIV OSAKA (JP) | 2020-07-01 | — | — | EP | disclosed |
| US-10695420-B2 | DNA-peptide combination vaccine | ANGES, INC. (JP) | 2020-06-30 | — | — | US | disclosed |
| US-10543261-B2 | DNA vaccine containing VEGF-specific epitope and/or angiopoietin-2-specific epitope | OSAKA UNIVERSITY (JP) | 2020-01-28 | — | — | US | disclosed |
| EP-2698164-B1 | DNA VACCINE | UNIV OSAKA (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9913886-B2 | DNA vaccine containing specific epitope of apolipoprotein (a) | ANGES, INC. (JP) | 2018-03-13 | — | — | US | disclosed |
| EP-3222289-A1 | DNA-PEPTIDE COMBINATION VACCINE | AnGes MG, Inc. (JP) | 2017-09-27 | — | — | EP | disclosed |
| US-20170258895-A1 | DNA-PEPTIDE COMBINATION VACCINE | ANGES MG, INC. (JP) | 2017-09-14 | — | — | US | disclosed |
| US-7718847-B2 | Method of gene introduction in in-vivo spermatogenic cell | KYOTO UNIVERSITY (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20090215644-A1 | Rna interference induction element and use thereof | KURUME UNIVERSITY (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-1932541-A1 | APOPTOSIS PROMOTER, CELL PROLIFERATION INHIBITOR, PROPHYLACTIC/THERAPEUTIC AGENT FOR CANCER, SCREENING METHOD FOR THE PROMOTER, INHIBITOR OR AGENT | OSAKA UNIVERSITY (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20080060091-A1 | Method of Gene Introduction in In-Vivo Spermatogenic Cell | KYOTO UNIVERSITY (JP) | 2008-03-06 | — | — | US | disclosed |
| US-6541649-B2 | A hydrophobic group is either directly linked to the positively charged Nitrogen atom or is linked to the said Nitrogen atom via an ester or methylene group. | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2003-04-01 | — | — | US | disclosed |
| US-6503945-B2 | Nontoxic, drug delivery, gene therapy; therapy of cystic fibrosis | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2003-01-07 | — | — | US | disclosed |
| US-20020077366-A1 | Novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2002-06-20 | — | — | US | disclosed |
| US-20020062044-A1 | Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH | 2002-05-23 | — | — | US | disclosed |
| US-6346516-B1 | DRUG DELIVERY OF (QUATERNARY) AMINE SALT AND MACROMOLECULE; GENE THERAPY | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2002-02-12 | — | — | US | disclosed |
| US-6333433-B1 | COUPLING ALIPHATIC ALDEHYDE WITH ALKYLAMINE, REDUCING IMINE TO SECONDARY AMINE, REACTING WITH PROTECTED HYDROXYALKYL HALIDE, DEPROTECTING, QUATERNIZING N-HYDROXYALKYL GROUP CONTAINING TERTIARY AMINE WITH ALKYL HALIDE OR TOSYLATE IN POLAR SOLVENT | COUNCIL OF SCIENTIFIC INDUSTRIAL RESEARCH (IN) | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077366-A1 | Novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules | NPC1L1, ABCB4, ANXA1 | ALDH1A1 3509/4885TP53 1078/4885CYP3A4 4856/4885 |
| US-20020062044-A1 | Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkyl group for intracellular delivery of biologically active molecules | CHMP4B, SLC43A1, SCAMP3 | ALDH1A1 4054/4885TP53 2065/4885CYP3A4 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.